Clinical trial

Gut Microbiota, Diet-INDuced Obesity and Type 2 Diabetes in New Caledonia - MIND

Opening soon · Not applicable · 0 countries · Registry ID NCT07205913

Opening soonNot applicableObservational

What this study is about

In recent years, the global rise in obesity and type 2 diabetes has become a major public health issue. In New Caledonia, 38% of the adult population has a body mass index ≥30. At the same time, the prevalence of type 2 diabetes continues to rise steadily. The burden of these diseases does not affect communities uniformly. While known factors such as diet, physical activity, and socioeconomic conditions play a role, studies have demonstrated the involvement of the gut microbiota in the development of metabolic disorders, particularly obesity and insulin resistance. However, this area remains largely unexplored in New Caledonia and the Pacific.

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age18 Years to Not listed
SexAll
Healthy volunteersAccepted
ConditionDiabetes Mellitus, Type 2, Obesity

Full registry criteria

Inclusion Criteria: * Aged between 18 and 60 years. * Ability to understand and provide informed consent. * Ability and willingness to meet the required schedule and study interventions. * Willingness to share their community belonging * Benefit from a social security system. For obese and diabetic patients : * IMC ≥ 30 kg/m² with type 2 diabetes * Fasting plasma glucose (FPG) ≥7 mM (=1.26g/l) or * Patients with HbA1c ≥ 6.5% (48 mmol/mol) * All stages of albuminuria For obese patients without type 2 diabetes * IMC ≥ 30 kg/m² * Weight stable for at least 2 months * Patients with normal glucose tolerance (NGT), impaired glucose tolerance (IGT) and/or impaired fasting glucose (IFG) and an HbA1c \< 6.5 % * No treatment (diabetic or weight loss) * Match age (±5years), sex and self-reported community to the patients from the1 group. For control group : * BMI between 18.5-24.9 kg/m² * Match age (±5years), sex and self-reported community to the patients from the 1 and 2 groups. * Participants with normal glucose tolerance (NGT), impaired glucose tolerance (IGT) and/or impaired fasting glucose (IFG) and an HbA1c \< 6.5 % Exclusion Criteria: All participants : * Treatment that may alter gastrointestinal motor function, acidity, microbial population, or immunosuppressants * Altered anatomy of the esophagus, stomach, small intestine, or large intestine due to gastrointestinal surgery (except appendectomy or cholecystectomy) * Chronic or acute inflammatory bowel disease or infections * Abdominal or pelvic radiation therapy or abdominal cancer, colorectal cancer * Dysphagia, eosinophilic esophagitis, esophageal stricture, or other swallowing disorders * Organ transplantation and patients receiving immunosuppressive therapy * Severe renal failure and/or patients undergoing dialysis * Cardiovascular, endocrine, renal, or other chronic disease that may affect motility. * Preparation for colon cleansing within the last month * \< 3 bowel movements per week * Women who are pregnant or breastfeeding

Treatments and study arms

25 ml blood sample

Other

A 25-ml blood sample

Urine sample

Other

A 10-ml urine sample

Stools

Other

10-g stools

40 ml blood sample

Other

A 40-ml blood sample

Primary outcomes

Describe and characterise the faecal microbiota of patients to investigate the relationships between microbiota composition with bioclinical parameters6 years

Microbiota will be analysed through 16S rRNA gene sequencing as well as shotgun metagenomic sequencing of the different samples obtained from the faecal sample

Describe and characterise the faecal microbiota and metabolome of patients to investigate the relationships between microbiota composition with bioclinical parameters6 years

microbiome and metabolites from collected human fecal samples will be analyzed using a standardized extraction protocol designed for Liquid chromatography-mass spectrometry (LC/MS)-based metabolomics to detect short-chain fatty acids and bile acids,…. which are mainly produced by bacteriasequencing of the different samples obtained from the faecal sample.

Study locations

0 locations were listed when this page was built. The first 40 are shown.

No public site location was included in this record. Check the original registry for updates.